Literature DB >> 25501291

Inhibition of 4-1BBL-regulated TLR response in macrophages ameliorates endotoxin-induced sepsis in mice.

Bo Ram Bang1, Sang Jick Kim, Hideo Yagita, Michael Croft, Young Jun Kang.   

Abstract

Activation of Toll-like receptor (TLR) signaling rapidly induces the expression of inflammatory genes, which is persistent for a defined period of time. However, uncontrolled and excessive inflammation may lead to the development of diseases. 4-1BB ligand (4-1BBL) plays an essential role in sustaining the expression of inflammatory cytokines by interacting with TLRs during macrophage activation. Here, we show that inhibition of 4-1BBL signaling reduced the inflammatory responses in macrophages and ameliorated endotoxin-induced sepsis in mice. A 4-1BB-Fc fusion protein significantly reduced TNF production in macrophages by blocking the oligomerization of TLR4 and 4-1BBL. Administration of 4-1BB-Fc suppressed LPS-induced sepsis by reducing TNF production, and the coadministration of anti-TNF and 4-1BB-Fc provided better protection against LPS-induced sepsis. Taken together, these observations suggest that inhibition of the TLR/4-1BBL complex formation may be highly efficient in protecting against continued inflammation, and that 4-1BB-Fc could be a potential therapeutic target for the treatment of inflammatory diseases.
© 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  4-1BBL; Inflammation; Innate immunity; Sepsis; TNF; Toll-like receptor signaling

Mesh:

Substances:

Year:  2015        PMID: 25501291      PMCID: PMC4418486          DOI: 10.1002/eji.201445174

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  27 in total

1.  The structure of tumor necrosis factor-alpha at 2.6 A resolution. Implications for receptor binding.

Authors:  M J Eck; S R Sprang
Journal:  J Biol Chem       Date:  1989-10-15       Impact factor: 5.157

2.  4-1BB-mediated immunotherapy of rheumatoid arthritis.

Authors:  Su K Seo; Jae H Choi; Young H Kim; Woo J Kang; Hye Y Park; Jae H Suh; Beom K Choi; Dass S Vinay; Byoung S Kwon
Journal:  Nat Med       Date:  2004-09-26       Impact factor: 53.440

Review 3.  The pathophysiology of tumor necrosis factors.

Authors:  P Vassalli
Journal:  Annu Rev Immunol       Date:  1992       Impact factor: 28.527

Review 4.  Development of anti-TNF therapy for rheumatoid arthritis.

Authors:  Marc Feldmann
Journal:  Nat Rev Immunol       Date:  2002-05       Impact factor: 53.106

5.  Expression and function of 4-1BB and 4-1BB ligand on murine dendritic cells.

Authors:  Toshiro Futagawa; Hisaya Akiba; Tomohiro Kodama; Kazuyoshi Takeda; Yasuyuki Hosoda; Hideo Yagita; Ko Okumura
Journal:  Int Immunol       Date:  2002-03       Impact factor: 4.823

6.  Blocking 4-1BB/4-1BB ligand interactions prevents herpetic stromal keratitis.

Authors:  Su K Seo; Hye Y Park; Jae H Choi; Won Y Kim; Young H Kim; Hyo W Jung; Byungsuk Kwon; Hyeon W Lee; Byoung S Kwon
Journal:  J Immunol       Date:  2003-07-15       Impact factor: 5.422

7.  Cell surface 4-1BBL mediates sequential signaling pathways 'downstream' of TLR and is required for sustained TNF production in macrophages.

Authors:  Young Jun Kang; Sung Ouk Kim; Shigeki Shimada; Motoyuki Otsuka; Alim Seit-Nebi; Byoung S Kwon; Tania H Watts; Jiahuai Han
Journal:  Nat Immunol       Date:  2007-05-13       Impact factor: 25.606

Review 8.  The role of tumor necrosis factor in sepsis.

Authors:  C E Spooner; N P Markowitz; L D Saravolatz
Journal:  Clin Immunol Immunopathol       Date:  1992-01

9.  Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group.

Authors:  C J Fisher; J M Agosti; S M Opal; S F Lowry; R A Balk; J C Sadoff; E Abraham; R M Schein; E Benjamin
Journal:  N Engl J Med       Date:  1996-06-27       Impact factor: 91.245

Review 10.  Resolution of inflammation: mechanisms and opportunity for drug development.

Authors:  Ana L Alessandri; Lirlândia P Sousa; Christopher D Lucas; Adriano G Rossi; Vanessa Pinho; Mauro M Teixeira
Journal:  Pharmacol Ther       Date:  2013-04-11       Impact factor: 12.310

View more
  6 in total

Review 1.  CD137 and CD137L signals are main drivers of type 1, cell-mediated immune responses.

Authors:  Bhushan Dharmadhikari; Meihui Wu; Nur Sharalyn Abdullah; Sakthi Rajendran; Nur Diana Ishak; Emily Nickles; Zulkarnain Harfuddin; Herbert Schwarz
Journal:  Oncoimmunology       Date:  2015-11-11       Impact factor: 8.110

2.  4-1BBL Regulates the Polarization of Macrophages, and Inhibition of 4-1BBL Signaling Alleviates Imiquimod-Induced Psoriasis.

Authors:  Haruka Miki; Kyung Ho Han; David Scott; Michael Croft; Young Jun Kang
Journal:  J Immunol       Date:  2020-02-10       Impact factor: 5.422

3.  The neutrophil elastase inhibitor, sivelestat, attenuates sepsis-related kidney injury in rats.

Authors:  Guofu Li; Jia Jia; Kaiqiang Ji; Xiaoying Gong; Rui Wang; Xiaoli Zhang; Haiyuan Wang; Bin Zang
Journal:  Int J Mol Med       Date:  2016-07-05       Impact factor: 4.101

Review 4.  Recent Advances in ADAM17 Research: A Promising Target for Cancer and Inflammation.

Authors:  Marcia L Moss; Dmitry Minond
Journal:  Mediators Inflamm       Date:  2017-11-02       Impact factor: 4.711

Review 5.  The Murine CD137/CD137 Ligand Signalosome: A Signal Platform Generating Signal Complexity.

Authors:  Beom K Choi; Hyeon-Woo Lee
Journal:  Front Immunol       Date:  2020-12-10       Impact factor: 7.561

Review 6.  Contribution of T- and B-cell intrinsic toll-like receptors to the adaptive immune response in viral infectious diseases.

Authors:  Ejuan Zhang; Zhiyong Ma; Mengji Lu
Journal:  Cell Mol Life Sci       Date:  2022-10-12       Impact factor: 9.207

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.